Navigation Links
Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results
Date:2/27/2012

160;31,
2011December 31,
2010ASSETSCash and cash equivalents$

114,094$

44,791Short-term investments55,69420,070Accounts receivable, net4,737909Inventories, net10,9243,140Prepaid expenses and other current assets4,1862,415Total current assets189,63571,325Property and equipment, net833809Deferred financing costs, net4,068—Restricted cash2,5801,284Total assets$

197,116$

73,418LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable$

7,046$

1,601Deferred revenues414428Accrued interest on Convertible Notes4,643—Other current liabilities17,96216,023Total current liabilities30,06518,052Convertible Notes, net of discount of $54,542175,458—Other liabilities36,099Commitments and contingenciesStockholders' Equity:Preferred stock—$.01 par value 4,000,000 shares authorized; no shares issued——Common stock—$.01 par value 150,000,000 shares authorized; issued and outstanding 71,502,000 in 2011 and 70,259,000 in 2010715703Additional paid-in-capital408,463364,139Accumulated deficit(417,603)(315,576)Accumulated other comprehensive income151Total stockholders' equity(8,410)49,267Total liabilities and stockholders' equity$

197,116$

73,418SAVIENT PHARMACEUTICALS, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share data)Three Months Ended
December 31,Year Ended
December 31,2011201020112010Revenues:Product sales, net$

3,710$

960$

9,565$

4,028Cost and expenses:Cost of goods sold3,3051,6759,3132,673Research and development7,4759,83724,79032,358Selling, general and administrative28,1378,21790,89824,98138,91719,729125,00160,012Operating loss(35,207)(18,769)(115,436)(55,984)Investment income, net4334150116Interest expense on convertible notes(4,344)—(15,737)—Other income (expense), net91918,2752,208(17,250)Loss before income taxes(38,589)(460)(128,815)(73,118)Income tax benefit(
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
2. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
3. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
4. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
5. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
6. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
7. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
8. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
9. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
10. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
11. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... LEXINGTON, Mass. , Dec. 23, 2014 /PRNewswire/ ... GEVA ), a biopharmaceutical company developing therapeutic products ... European Medicines Agency (EMA) of the Marketing Authorization ... The EMA recently granted the company,s request for ... the EMA,s regulatory review time.   ...
(Date:12/24/2014)... Va. , Dec. 23, 2014  The ... diastolic blood pressure target for people with diabetes ... moderate or high doses of statins, in keeping ... management enacted by the American College of Cardiology ... are reflected in the most recent changes to ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... Sciences, Inc., a,privately held biopharmaceutical company developing ... BSI-401 inhibited pancreatic cancer,cell growth in vitro ... combination with,oxaliplatin. BSI-401 is BiPar,s second-generation product ... as PARP (poly-ADP-ribose polymerase) inhibitors. Researchers ...
... sleep apnea and sleep behavior,disorders, ROCHESTER, Minn., ... diagnosing and treating patients with a,variety of sleep ... at CHEST 2007, the annual meeting of the ... 20-25. The following are,brief summaries of select presentations., ...
Cached Medicine Technology:BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor 2Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 2Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 3Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 4
(Date:12/25/2014)... 25, 2014 Product liability lawsuits filed ... recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in ... Order issued in the U.S. District Court, Northern District ... an open conference on January 7, 2015, at the ... in West Palm Beach, Florida. The Conference is scheduled ...
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... with complex chronic illnesses can receive effective, less expensive care ... easy access to a team of dedicated health care professionals, ... become seriously ill and need either hospitalization or a trip ... enhanced medical home clinic at the University of Texas in ...
(Date:12/25/2014)... tries its best to translate the experience of dress ... introduced its new collection of 2015 prom dresses, and ... prom outfits are guaranteed to contain the perfect designs ... designed for 2015. Anyone who wants to buy ... before Jan. 26, 2015, the deadline of the promotion. ...
(Date:12/25/2014)... Rosa, CA (PRWEB) December 25, 2014 ... department visits and 2 million hospital admissions across the ... and Prevention ). The CDC’s National Hospital Ambulatory ... departments through a survey conducted in 2010. They estimated ... department visits that resulted in a primary diagnosis of ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... is pleased to announce the opening of attendee registration ... Technology Exposition and Conference. This year,s event will be ... Stephens Convention Center in Rosemont, Illinois. OMTEC is the ... industry professionals involved in all facets of the supply ...
... year by a Cornell researcher add to growing evidence that ... of other fruits and vegetables -- can help keep the ... in the Journal of Agricultural and Food Chemistry ... and a member of Cornell,s Institute for Comparative and Environmental ...
... manifested in a variety of tissues and cancer cells ... being studied as a novel treatment. The PPAR-gamma ligand ... differentiation, apoptotic induction, and changes in genes or proteins ... been some reports suggesting that stomach cancer cells manifest ...
... been used as the "gold standard" for the assessment of ... possible complications of this procedure, for both, the physician and ... not trivial one. So, scientists tend to introduce non-invasive methods ... to be published on February 7, 2009 in the ...
... researcher Dr. Daniel Von Hoff and his team at ... developing novel therapies for patients with pancreatic cancer. They ... vulnerability." Dr. Von Hoff provides case studies and ... promising discoveries and is changing the future of oncology ...
... wartime conditions, researchers say , , TUESDAY, Feb. 17 (HealthDay ... be exacerbated by combat conditions in Iraq and Afghanistan ... evacuated for treatment, a new report finds. , In ... for poor morale and combat ineffectiveness, the researchers noted ...
Cached Medicine News:Health News:OMTEC Registration Opens - Education for a Competitive Advantage in Orthopaedics 2Health News:In flurry of studies, researcher details role of apples in inhibiting breast cancer 2Health News:What is the suppressing effect of the PPAR-gamma ligands on stomach cancer cells? 2Health News:Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development 2Health News:Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development 3Health News:Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development 4Health News:Skin Woes Take Toll on U.S. Combat Troops 2Health News:Skin Woes Take Toll on U.S. Combat Troops 3
VG2 PLIF (Trapezoid) Posterior lumbar interbody fusion. Frozen preservation. Consists of two outer cortical planks, center cancellous plank, all from the same donor, held together by two press-fit co...
VG1 ALIF (Anterior Lateral) Anterior lumbar interbody fusion. Frozen freeze-dried preservation....
... Corlok Allografts are unique corticocancellous ... face and a unique Dovetail geometry ... adjacent vertebrae. Corlok Allografts are processed ... spinal allograft implants. Specially designed instruments ...
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Medicine Products: